The WACC of American Vietnamese Biotech Inc (AMV.VN) is 12.0%.
| Range | Selected | |
| Cost of equity | 12.60% - 19.10% | 15.85% |
| Tax rate | 1.90% - 4.30% | 3.10% |
| Cost of debt | 4.00% - 7.00% | 5.50% |
| WACC | 9.4% - 14.5% | 12.0% |
| Category | Low | High |
| Long-term bond rate | 2.7% | 3.2% |
| Equity market risk premium | 9.5% | 10.5% |
| Adjusted beta | 1.04 | 1.46 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 12.60% | 19.10% |
| Tax rate | 1.90% | 4.30% |
| Debt/Equity ratio | 0.59 | 0.59 |
| Cost of debt | 4.00% | 7.00% |
| After-tax WACC | 9.4% | 14.5% |
| Selected WACC | 12.0% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for AMV.VN:
cost_of_equity (15.85%) = risk_free_rate (2.95%) + equity_risk_premium (10.00%) * adjusted_beta (1.04) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.